University of Lille II - Institut Pasteur de Lille, University of Lille II - Center for Infection and Immunity of Lille, University of Lille II - Center for Infection and Immunity of Lille, Université de Toulouse, University of Lille II - Institut Pasteur de Lille, BioVersys SAS, University of Lille II - Center for Infection and Immunity of Lille, University of Lille II - Center for Infection and Immunity of Lille, University of Lille II - Center for Infection and Immunity of Lille, University of Lille II - Center for Infection and Immunity of Lille, BioVersys SAS, University of Lille II - Center for Infection and Immunity of Lille, Université Libre de Bruxelles (ULB), BioVersys SAS, Université de Toulouse, Université de Toulouse, University of Lille II - Center for Infection and Immunity of Lille, University of Lille II - Center for Infection and Immunity of Lille, University of Lille II - Center for Infection and Immunity of Lille, Université de Toulouse, BioVersys AG, Basel, Université de Toulouse, University of Lille II - Institut Pasteur de Lille, Université de Toulouse, Université Libre de Bruxelles (ULB), University of Lille II - Institut Pasteur de Lille and Independent

Uppsala University, University of Zaragoza, Critical Path Institute, Ltd. (C-Path) Europe, Research Center Borstel - Molecular and Experimental Mycobacteriology, University of Lille II - Center for Infection and Immunity of Lille, University of Lille II - Center for Infection and Immunity of Lille, University of Lille II - Center for Infection and Immunity of Lille, University of Zaragoza, University of Cologne, University of Cologne, University of Padua, University of Padua - Department of Molecular Medicine, University of Padua - Department of Molecular Medicine, University of Padua - Department of Molecular Medicine, University of Pavia, University of Pavia, University of Pavia - Department of Biology and Biotechnology, Uppsala University and University of Zaragoza - Department of Microbiology